US FDA · Compliance programme
FDA issues inspection programme for CDER-regulated biologics
Official source date: · Source checked
Programme 7346.832M addresses prelicense and preapproval inspections supporting original and supplemental biologics licence applications. Its stated implementation date is 14 May 2026.
Who should review this?
Manufacturers and applicants for biological products regulated by CDER.
What it means for pharmaceutical teams
This document guides a defined prelicense and preapproval inspection programme. Its issue date and implementation date are different. It should not be treated as a universal inspection programme for every product regulated by FDA.
Practical review checklist
PharmaEdges reading prompts for your own applicability review:
- Confirm that the product and application fall within programme 7346.832M.
- Read the inspectional sections alongside the manufacturing commitments in the application.
- Use the source to inform a documented readiness review with the appropriate quality and regulatory personnel.
Official source and verification
Read the US FDA source (opens in a new tab)
This article summarises the linked official material. The context and checklist are PharmaEdges explanatory commentary, not additional regulatory requirements. The source publication date is separate from this article’s publication date.
For a correction, contact PharmaEdges with the article URL and supporting source. Read our news publishing policy.
Related fda intelligence
- FDA finalises guidance on postapproval biosimilar manufacturing changes
- FDA publishes final ICH E2B(R3) guidance for electronic safety reports
- FDA proposes updated principles for container closure quality
- FDA proposes guidance on responding to Form 483 observations